# SC-102

Source: https://onco.cc/drugs/sc-102/  
OnCo record `sc-102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SC-102 is an experimental peptide-drug conjugate from ConjuStar Biologics, in phase 1 trials for ephA2-expressing advanced or metastatic solid tumours.

## Summary

SC-102 is a peptide-drug conjugate from ConjuStar Biologics. A peptide-drug conjugate made of an EphA2-targeting peptide, a tubulin-inhibitor payload and a protease-cleavable linker. Its furthest stage is phase 1, for ephA2-expressing advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. US FDA IND clearance announced 4 June 2025 (company news); phase 1 recruiting (NCT06710158). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: SC-102
- Modality: Peptide-drug conjugate
- Mechanism: A peptide-drug conjugate made of an EphA2-targeting peptide, a tubulin-inhibitor payload and a protease-cleavable linker.

## Sources

- ConjuStar Biologics: conjustar.com: https://www.conjustar.com/
- ConjuStar Biologics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06710158
- ClinicalTrials.gov: trials of SC-102: https://clinicaltrials.gov/search?intr=SC-102

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [EphA2 receptor](https://onco.cc/targets/epha2/)
- companies: [ConjuStar Biologics](https://onco.cc/companies/conjustar-biologics/)
- trials: [Study of SC-102 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06710158/)

---
JSON: https://onco.cc/api/v1/entities/sc-102.json